Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) Viatris (Nasdaq: VTRS) announced MHLW approval of Effexor SR 37.5 mg / 75 mg for adults with generalized anxiety disorder (GAD) in Japan on March 23, 2026.This makes Effexor the first and only approved GAD treatment in Japan; approval is supported by a Phase 3 trial (p=0.012) and long-term extension data.

#VTRS Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

www.stocktitan.net/news/VTRS/viatris-advanc...

$11B cash by 2030 gives Viatris room for deals and shareholder returns Base case targets call for more than $2.7B in 2030 free cash flow, with about 50% of deployable cash earmarked for business development.

#VTRS Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

www.stocktitan.net/news/VTRS/viatris-to-out...

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results Viatris (Nasdaq: VTRS) reported Q4 2025 total revenues of $3.7B and FY2025 total revenues of $14.3B, met or exceeded 2025 guidance across key metrics, and returned over $1B to shareholders. The company completed an enterprise strategic review, expects up to $650M in net cost savings, and provided 2026 guidance while noting multiple upcoming regulatory milestones and an expected workforce reduction of up to 10%.Key financials: Q4 adjusted EBITDA of $1.003B, Q4 adjusted EPS of $0.57, FY adjusted EBITDA of $4.16B, FY free cash flow of $1.94B, and a FY U.S. GAAP net loss of $(3.51B) reflecting a $2.9B goodwill impairment.

#VTRS Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/VTRS/viatris-report...

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure Viatris (Nasdaq: VTRS) announced the launch of Inpefa (sotagliflozin) in the United Arab Emirates, the first market within Viatris territories to commercialize the drug, with additional launches planned across multiple countries over the next several years.Inpefa is the first dual SGLT1/2 inhibitor approved to reduce risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits. Approval is supported by two Phase 3 trials (SOLOIST-WHF and SCORED; >11,800 patients) showing a 33% reduction in the composite endpoint in SOLOIST-WHF (up to 51% when initiated prior to discharge), 25% reduction in SCORED, and a 23% reduction in MACE, including 32% reduction in MI and 34% reduction in stroke.

#LXRX #VTRS Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

www.stocktitan.net/news/LXRX/viatris-expand...

📢 Stocks Trending NOW: #C #BAC #WFC #MSTR #CRM #ROLR #ADBE #MRNA #ANET #VTRS

Viatris Provides Pipeline Update on Four Regulatory Milestones Receives U.S. Food and Drug Administration Approval for Generic Version of Sandostatin ® LAR Depot U.S. FDA Accepts New Drug Application for Low Dose Estrogen Weekly Patch for Contraception U.S. FDA Clears Investigational New Drug Application for MR-146 in Neurotrophic Keratopathy Japan Pharmaceuticals and Medical Devices Agency Accepts Japanese New...

#VTRS Viatris Provides Pipeline Update on Four Regulatory Milestones

www.stocktitan.net/news/VTRS/viatris-provid...

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited Oculis (Nasdaq: OCS) will highlight its late-stage ophthalmology pipeline at Eyecelerator and the AAO Annual Meeting in Orlando on October 16-20, 2025.Key updates include the acceleration of Privosegtor into registrational trials after a positive FDA meeting, topline readouts from the Phase 3 DIAMOND program for OCS-01 in diabetic macular edema expected in Q2 2026, and the planned start of the genotype-based PREDICT-1 registrational trial for Licaminlimab anticipated in Q4 2025. Presenters include CEO Riad Sherif, MD and retina advisor Arshad M. Khanani, MD.

#VTRS Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

www.stocktitan.net/news/VTRS/viatris-announ...

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business Makes Late-Stage Pipeline Progress Including NDA Submission for Low-Dose Estrogen Weekly Patch Acquires Aculys Pharma Including Rights to Pitolisant in Japan and Spydia ® in Japan and Certain Other Markets in the Asia-Pacific Region Returns More...

#VTRS Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance

www.stocktitan.net/news/VTRS/viatris-report...

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. Viatris (NASDAQ:VTRS) has received FDA approval for the first generic version of Iron Sucrose Injection, USP, used to treat iron deficiency anemia in chronic kidney disease patients. The product will be available in three strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL.The company secured Competitive Generic Therapy (CGT) designation for two strengths, granting 180 days of exclusivity. The reference drug, Venofer®, had annual U.S. sales of $515M as of June 2025. This approval demonstrates Viatris' capabilities in developing complex generic medicines and strengthens its injectable pipeline, which includes other iron replacement products like ferric carboxymaltose injection.

#VTRS Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.

www.stocktitan.net/news/VTRS/viatris-announ...

Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance Viatris (NASDAQ:VTRS) reported strong Q2 2025 results, with total revenues of $3.58 billion, down 6% year-over-year but exceeding expectations. The company's adjusted EPS reached $0.62, while adjusted EBITDA was $1.1 billion. Despite challenges, Viatris demonstrated resilience across its global business segments.Key highlights include positive results from five Phase 3 clinical trials and significant capital returns to shareholders totaling $630 million year-to-date, including $350 million in share buybacks. The company reiterated its 2025 financial guidance, expecting to perform in the top half of the range for total revenues and adjusted EPS.Regional performance showed strength in Greater China with 9% growth, while other markets faced some headwinds. The company continues to advance its late-stage pipeline and maintains its commitment to strategic growth initiatives for 2026 and beyond.

#VTRS Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance

www.stocktitan.net/news/VTRS/viatris-report...

Viatris' New Fast-Acting Pain Drug Could Reduce Opioid Use: Phase 3 Data Reveals Breakthrough Results New Phase 3 data shows Viatris' fast-acting meloxicam effectiveness in post-surgery pain management with potential opioid-sparing benefits. See full results.

#VTRS Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference

www.stocktitan.net/news/VTRS/viatris-announ...

Viatris Blepharitis Treatment Falls Short in Phase 3 Trial, But Pipeline Shows Promise MR-139 fails to meet efficacy goals for blepharitis treatment, while Viatris advances other eye therapies. See latest pipeline developments and next steps.

#VTRS Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

www.stocktitan.net/news/VTRS/viatris-provid...

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia Viatris (NASDAQ:VTRS) announced positive top-line results from its VEGA-3 Phase 3 trial for MR-141, a treatment for presbyopia. The randomized, placebo-controlled study involving 545 patients met its primary and all secondary endpoints, demonstrating significant improvement in near vision without compromising distance vision.The trial showed statistically significant results (p<0.0001) in achieving ≥3-line gain in binocular distance-corrected near visual acuity. Patients reported significant functional benefits and satisfaction with near vision improvements, particularly in dim lighting conditions. The safety profile remained consistent with previous trials, with no treatment-related serious adverse events.Viatris plans to submit an FDA application in H2 2025 for MR-141, targeting a condition that affects approximately 90% of U.S. adults over 45.

#VTRS Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

www.stocktitan.net/news/VTRS/viatris-announ...

Pomerantz Law Firm Signals Class Action Lawsuit Against Viatris Inc. with Important Deadlines for Investors Investors in Viatris Inc. should be aware of a class action lawsuit concerning potential securities fraud, with significant deadlines approaching for participation.

Pomerantz Law Firm Signals Class Action Lawsuit Against Viatris Inc. with Important Deadlines for Investors #USA #New_York #Pomerantz #Viatris #VTRS

Viatris Inc. Shareholders Invited to Lead Class Action Against Securities Fraud Allegations Investors in Viatris Inc. who have incurred significant losses may take charge in a proposed class action lawsuit related to alleged securities fraud. Details here.

Viatris Inc. Shareholders Invited to Lead Class Action Against Securities Fraud Allegations #United_States #Securities_Fraud #Bensalem #Viatris #VTRS

Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook Viatris (VTRS) reported Q1 2025 financial results with total revenues of $3.3 billion, down 11% year-over-year, but in line with expectations. The company posted a net loss of $3.0 billion, primarily due to a $2.9 billion goodwill impairment charge. Key metrics include adjusted EBITDA of $923 million and adjusted EPS of $0.50. Viatris returned over $450 million to shareholders year-to-date through share repurchases and dividends. The company made significant pipeline progress with three positive Phase 3 data readouts, including EFFEXOR for Japan, a novel meloxicam formulation, and XULANE LO contraceptive patch. Viatris reaffirmed its 2025 guidance with total revenues expected between $13.5-14.0 billion and adjusted EPS of $2.16-2.30.

#VTRS Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook

www.stocktitan.net/news/VTRS/viatris-report...

Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential Viatris (NASDAQ: VTRS) announced positive Phase 3 study results for its investigational XULANE LO™ low dose contraceptive patch. The study, involving 1,272 women across 81 sites in the U.S., Puerto Rico, and Canada, demonstrated favorable efficacy with a Pearl Index of 4.14 and a 3.7% cumulative pregnancy probability over 13 cycles.The patch showed strong performance metrics, including excellent adhesion with only 1.3% of patches completely detaching during the seven-day wearing period and less than 1% of subjects reporting severe local application site reactions. Most treatment emergent adverse events were mild-to-moderate, with favorable cycle control and low unscheduled bleeding events. Viatris plans to submit a New Drug Application to the FDA in the second half of 2025.

#VTRS Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential

www.stocktitan.net/news/VTRS/viatris-announ...

The Gross Law Firm Urges Viatris Investors to Act Before June 3, 2025 Lead Plaintiff Deadline The Gross Law Firm is notifying Viatris Inc. shareholders of an important lead plaintiff deadline on June 3, 2025. Take action now for your rights!

The Gross Law Firm Urges Viatris Investors to Act Before June 3, 2025 Lead Plaintiff Deadline #Gross_Law_Firm #Viatris_Inc. #VTRS

Viatris Shareholders Encouraged to Act: Class Action Deadline Approaches Investors with losses over $100,000 in Viatris must act quickly. The deadline for filing lead plaintiff applications for a class action lawsuit is June 3, 2025.

Viatris Shareholders Encouraged to Act: Class Action Deadline Approaches #USA #New_Orleans #ClaimsFiler #Viatris_Inc #VTRS

Class Action Lawsuit Filed Against Viatris Inc. Amid Investor Concerns and SEC Scrutiny Investors in Viatris, Inc. are alerted to a class action lawsuit regarding potential securities fraud. Important deadlines ahead for claimants.

Class Action Lawsuit Filed Against Viatris Inc. Amid Investor Concerns and SEC Scrutiny #United_States #New_York #Pomerantz_Law #Viatris #VTRS

#VTRS 10C 2027 leaps.

$VTRS struggles to hold momentum.
After a brief push, sellers took control, dragging the price back to $9.15. With volume ticking up, is this a breakdown or a buying opportunity? 🤔

Watch for key support levels!

#StockMarket #VTRS #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GSBD, #NDAQ, #VTRS, #TALO, #AAOI

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GSBD, #TTD, #QCOM, #NDAQ, #VTRS

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#TALO, #AAOI, #GSBD, #ESTA, #VTRS

#OptionFlow #OptionsTrading #Trading

HeatMaps - ORTEX

📈 Earnings Dropped This Morning!

Notable reports from #DQ, #GEO, #NCLH, #VST, #VTRS, #VRNA, and more.

See how the market is reacting with ORTEX’s Earnings HeatMap.

app.ortex.com/earnings/hea...

#Earnings #Trading #Investing #ORTEX

Viatris Earnings: $500M Revenue Hit Expected From FDA Warning as Company Unveils 2025 Strategy Viatris reported $14.7B in revenue and $4.7B adjusted EBITDA, meeting 2024 targets while facing $500M revenue impact from FDA import alert at Indore facility.

#VTRS Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance

www.stocktitan.net/news/VTRS/viatris-report...

Viatris's Lupus Drug Cenerimod Shows Powerful Disease Activity Improvement in Phase 2b Clinical Trial Landmark Phase 2b study reveals Viatris's cenerimod significantly reduces lupus disease activity with promising safety profile. Key findings published in Lancet Rheumatology.

#VTRS Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology

www.stocktitan.net/news/VTRS/viatris-announ...

JUST IN: ( NASDAQ: #VTRS ) Viatris Reports Third Quarter Financial Results for 2024

#StockMarket #News

Breaking News: ( NASDAQ: #VTRS ) Viatris 2023 Sustainability Report: Addressing Critical Health and Social Needs in India

#StockMarket #News